A comprehensive computational analysis to explore the importance of SIGLECs in HCC biology
Background Hepatocellular carcinoma (HCC) is an aggressive, malignant cancer with a complex pathogenesis. However, effective therapeutic targets and prognostic biomarkers are limited. Sorafenib provides delaying cancer progression and survival improvement in advanced HCC. But despite 10 years of research on the clinical application of sorafenib, predictive markers for its therapeutic effect are lacking. Methods The clinical significance and molecular functions of SIGLEC family members were assessed by a comprehensive bioinformatic analysis. The datasets included in this study (ICGC-LIRI-JP, GSE22058 and GSE14520) are mainly based on patients with HBV infections or HBV-related liver cirrhosis. The TCGA, GEO, and HCCDB databases were used to explore the expression of SIGLEC family genes in HCC. The Kaplan–Meier Plotter database was used to evaluate relationships between the expression levels of SIGLEC family genes and prognosis. Associations between differentially expressed genes in the SIGLEC family and tumour-associated immune cells were evaluated using TIMER. Results The mRNA levels of most SIGLEC family genes were significantly lower in HCC than in normal tissues. Low protein and mRNA expression levels of SIGLECs were strongly correlated with tumour grade and clinical cancer stage in patients with HCC. Tumour-related SIGLEC family genes were associated with tumour immune infiltrating cells. High SIGLEC expression was significantly related to a better prognosis in patients with advanced HCC treated with sorafenib. Conclusions SIGLEC family genes have potential prognostic value in HCC and may contribute to the regulation of cancer progression and immune cell infiltration. More importantly, our results revealed that SIGLEC family gene expression may be used as a prognostic marker for HCC patients treated with sorafenib..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
BMC gastroenterology - 23(2023), 1 vom: 18. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yao, Senbang [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Hepatocellular carcinoma |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s12876-023-02672-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR05146537X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR05146537X | ||
| 003 | DE-627 | ||
| 005 | 20230510063450.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230508s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12876-023-02672-z |2 doi | |
| 035 | |a (DE-627)SPR05146537X | ||
| 035 | |a (SPR)s12876-023-02672-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yao, Senbang |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A comprehensive computational analysis to explore the importance of SIGLECs in HCC biology |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background Hepatocellular carcinoma (HCC) is an aggressive, malignant cancer with a complex pathogenesis. However, effective therapeutic targets and prognostic biomarkers are limited. Sorafenib provides delaying cancer progression and survival improvement in advanced HCC. But despite 10 years of research on the clinical application of sorafenib, predictive markers for its therapeutic effect are lacking. Methods The clinical significance and molecular functions of SIGLEC family members were assessed by a comprehensive bioinformatic analysis. The datasets included in this study (ICGC-LIRI-JP, GSE22058 and GSE14520) are mainly based on patients with HBV infections or HBV-related liver cirrhosis. The TCGA, GEO, and HCCDB databases were used to explore the expression of SIGLEC family genes in HCC. The Kaplan–Meier Plotter database was used to evaluate relationships between the expression levels of SIGLEC family genes and prognosis. Associations between differentially expressed genes in the SIGLEC family and tumour-associated immune cells were evaluated using TIMER. Results The mRNA levels of most SIGLEC family genes were significantly lower in HCC than in normal tissues. Low protein and mRNA expression levels of SIGLECs were strongly correlated with tumour grade and clinical cancer stage in patients with HCC. Tumour-related SIGLEC family genes were associated with tumour immune infiltrating cells. High SIGLEC expression was significantly related to a better prognosis in patients with advanced HCC treated with sorafenib. Conclusions SIGLEC family genes have potential prognostic value in HCC and may contribute to the regulation of cancer progression and immune cell infiltration. More importantly, our results revealed that SIGLEC family gene expression may be used as a prognostic marker for HCC patients treated with sorafenib. | ||
| 650 | 4 | |a Hepatocellular carcinoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sorafenib |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Prognostic markers |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immunotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tumour progression |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Chen, Wenjun |4 aut | |
| 700 | 1 | |a Chen, Tingting |4 aut | |
| 700 | 1 | |a Zuo, He |4 aut | |
| 700 | 1 | |a Bi, Ziran |4 aut | |
| 700 | 1 | |a Zhang, Xiuqing |4 aut | |
| 700 | 1 | |a Pang, Lulian |4 aut | |
| 700 | 1 | |a Jing, Yanyan |4 aut | |
| 700 | 1 | |a Yin, Xiangxiang |4 aut | |
| 700 | 1 | |a Cheng, Huaidong |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC gastroenterology |d London : BioMed Central, 2001 |g 23(2023), 1 vom: 18. Feb. |w (DE-627)SPR027401618 |w (DE-600)2041351-8 |x 1471-230X |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:18 |g month:02 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12876-023-02672-z |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 18 |c 02 | ||